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OPENING ONE’S EYES TO MOSAICISM IN
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA
Autosomal dominant progressive external ophthalmo-
plegia (adPEO) is a mendelian disorder of mitochon-
drial DNA (mtDNA) maintenance characterized by
restricted eye movements, ptosis, and skeletal muscle–
restricted multiple mtDNA deletions.1 Dominantly in-
herited pathogenic variants of TWNK (GenBank:
NM_021830), encoding twinkle helicase, an essential
protein required to unwind mtDNA during replication,
are among the most common cause of adult-onset
PEO,2,3 with patients manifesting relatively indolent
PEO phenotypes, often with proximal muscle weakness,
ataxia, visual loss or impairment, and neurologic symp-
toms.1 However, after excluding pathogenic variants in
known genes, the genetic etiology remains undeter-
mined in approximately 50% of patients. We describe
the diagnostic odyssey of a patient who presented in the
fourth decade of life with PEO and harbored a mosaic
known pathogenic TWNK variant, initially undetected
by conventional diagnostic Sanger sequencing but iden-
tified using next-generating sequencing.
A 41-year-old woman initially presented with
a 9-year history of progressive ptosis associated with
intermittent diplopia. Clinical examination revealed
bilateral, asymmetric ptosis (right. left), external oph-
thalmoplegia, mild facial weakness, and mild proximal
myopathy (Medical Research Council 4/5). Family his-
tory was unremarkable. Initially, she was investigated
for myasthenia gravis that proved negative (tensilon
test, repetitive nerve stimulation, and acetylcholine
receptor antibodies). Electromyography showed only
slight myopathic changes; the muscle creatine kinase
level was elevated at 994U/L (range 0–160); and lactate
levels were normal (1.1 mmol/L; range 0.7–2.1). Mus-
cle biopsy showed 20% cytochrome c oxidase–deficient
fibers, many of which showed increased succinate
dehydrogenase reactivity, typical of “ragged-blue” fibers
(figure, A). Southern blotting of muscle DNA revealed
multiple mtDNA deletions (figure, B), which were also
previously confirmed by a quantitative real-time PCR
assay4; our patient corresponds to subject M1 in the
original publication.4
Candidate screening of nuclear genes associated
with PEO and multiple mtDNA deletions (POLG,
RRM2B, SLC25A4, TWNK, POLG2, TK2, and
RNASEH1) were apparently negative, prompting
whole-exome sequencing with blood DNA. The
mean depth per exome consensus coding sequence
(CCDS) was 71-fold, while the mean percentage of
CCDS bases at 20-fold coverage was 87.01%. Anal-
ysis of rare exonic variants in nuclear genes encoding
mitochondrial-localized proteins or DNA transcrip-
tion, replication, or maintenance machinery unex-
pectedly revealed a known pathogenic heterozygous
c.1121G.A p.(Arg374Gln) TWNK variant.2,3 Analysis
of additional genes associated with mtDNA mainte-
nance disorders failed to detect pathogenic variants.
Examination of read coverage at the c.1121 base (UCSC
hg19, g.102749088) showed 30 reads that passed qual-
ity score filtering, with an unfiltered allele depth of 20
reads indicating wild-type and 10 reads indicating the
variant (c.1121G.A, p.Arg374Gln) (figure e-1, http://
links.lww.com/NXG/A8). Re-examination of the diag-
nostic electropherograms for TWNK from blood
DNA revealed a small peak for the c.1121G.A
p.(Arg374Gln) variant, which was confirmed by
repeated Sanger sequencing of both blood and
muscle DNA, suggestive of low-level mosaicism
(figure, C). Targeted next-generation sequencing
was subsequently performed to achieve a higher
depth of coverage at the variant nucleotide and allow
a more accurate estimation of the levels of mosaicism
in these tissues. A read depth of .1,700 was
observed in both tissues, and the levels of mosaicism
were determined to be 13% in blood and 18% in
muscle (figure e-2, http://links.lww.com/NXG/A9).
Somatic mosaicism is the phenomenon of a single
variant occurring in 2 or more populations of soma
cells in 1 individual and has been increasingly recog-
nized as an important pathogenic mechanism in
genetic disease.5 Probable germline mosaicism of
dominant pathogenic TWNK and SLC25A4 variants
causing adult-onset PEO with multiple mtDNA de-
letions have been previously described.6,7 By contrast,
we present evidence of somatic mosaicism for a path-
ogenic TWNK variant associated with this disorder.
Due to the low level of mosaicism (18%) in skeletal
muscle, we speculate that the variant may have arose
during early embryogenesis,5 manifesting in a rela-
tively indolent clinical phenotype. Despite low-level
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mosaicism, the variant could be highly detrimental to
hexamer formation and helicase activity. Further-
more, diagnostic Sanger sequencing of TWNK ini-
tially failed to identify the mosaic variant, and
hence, genetic analysis was reported as negative.
While autosomal dominant disorders have a 50%
recurrence risk in offspring, mosaicism also presents
a considerable recurrence risk. For our patient, it was
not possible to determine the extent of mosaicism in
the germline, which provides further challenges for
genetic counseling. Nonetheless, we provided
a genetic diagnosis in a longstanding case, demon-
strating the use of next-generation sequencing for
detecting and quantifying low-level mosaicism.
In conclusion, we suggest that physicians should
revisit suspected adPEO patients with apparently
negative genetic testing of mtDNA maintenance
disorder genes and to consider mosaicism. With
expanded reproductive options and ongoing devel-
opment of therapeutic strategies, our case high-
lights the importance of attaining a genetic
diagnosis and the power of next-generation
sequencing.
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